GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
- Conditions
- Metastatic Melanoma, BRAF V600 Mutation Positive
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02608034
- Locations
- 🇮🇱
Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel
🇰🇷Samsung Medical Center; Gastroenterology, Seoul, Korea, Republic of
🇷🇺FSBSI "N. N. Blokhin Russian Cancer Research Center", Moscow, Russian Federation
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02596399
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT02593331
- Locations
- 🇺🇸
Profil Institute for Clinical Research Inc., Chula Vista, California, United States
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
- Conditions
- Urothelial Carcinoma
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02589717
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02569801
- Locations
- 🇺🇸
Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States
🇺🇸The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02536391
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02536339
- Locations
- 🇺🇸
Temple Cancer Center; Oncology, Philadelphia, Pennsylvania, United States
🇺🇸Methodist Hospital Research Institute, Houston, Texas, United States
🇺🇸Dana Farber Cancer Inst., Boston, Massachusetts, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02528903
- Locations
- 🇨🇦
inVentiv Health Clinique, Quebec, Canada
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT02510794
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸N CA Retina Vitreous Assoc, Mountain View, California, United States
🇺🇸Retina Research Center, Austin, Texas, United States
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Lymphocytic Leukemia, ChronicLymphoma, Non Hodgkin
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 713
- Registration Number
- NCT02500407
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Sansum Medical Clinic, Inc., Santa Barbara, California, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States